Skip to content

Clinical trial on eye health

A Randomized, double-blind, three arm, placebo-controlled clinical study to evaluate the modulatory effect of Lutein and Zeaxanthin supplementation (Gleamax / Vividawn) on MPOD levels along with Glare disability and Contrast enhancement in healthy subjects. - NIL

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/12/060711
Enrollment
150
Registered
2023-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Lutein- Zeaxanthin (10:2): Dose:500mg (Each capsule contains 12mg of Lutein Zeaxanthin (10:2) Dosage form: Capsules Duration: 90 days 1 capsule per day, after breakfast Intervention2

Sponsors

BOTANIC HEALTHCARE PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Volunteers of either sex, between 45 to 65 years of age. 2. Patients with exudative AMD 3. Volunteers with MPOD level between 0.2 to 0.4 d.u. 4. Total cholesterol level less than 6.2mmol L 5. Volunteers having no clinically significant ocular pathological condition, but clinically non-significant problem with accommodation of the eye can be included. 6. Negative HIV 1 and 2 and HBsAG. 7. Willing to come for regular follow up visits. 8. Able to give written informed consent, willingness to take part in study and able to attend all scheduled visits. 9. BMI 25 to 33 kg m2

Exclusion criteria

Exclusion criteria: 1. Not willing to sign the ICF or give the consent 2. Taking Drugs Medication a. Drug addicts b. People on hyperlipidemia medications and controlled diets c. People on hormone replacement therapy d. Regular users of supplements or dietary supplements 3. Medical conditions a. People with hyperlipidemia, hyper cholesterolemia, renal disorder, liver disorder, diabetes mellitus and other debilitating diseases. b. People with additional ophthalmic dieses will be excluded. c. People undergoing retinal surgery and retinal laser treatment to be excluded. d. People with macular atrophy e. Those with signs of exudative changes in the retina, including sub retinal fluid, pigment epithelial detachment, or hemorrhage. f. Myopia of more than 6 diopters g. Those with cataracts or corneal opacity, glaucoma, pan retinal degeneration h. People who have undergone any surgery. 4. Other general information physiological, lifestyle, allergic reactions, etc a. Pregnant and lactating women or those planning to become pregnant b. Those with allergies adverse reactions to the test substance c. Alcohol consumption men greater than or equal to 40 g per day, women greater than or equal to 20 g per day according to WHO guidelines for daily alcohol consumption d. Excessive smokers greater than or equal to 20 cigarettes per day. e. Taking a dietary supplement related to the function within 3 months prior to the start of the study. f. Participation in another clinical trial within the last 3 months. g. Subjects who, in the opinion of the investigator, are unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
1. Changes in MPOD levels 2. Changes in glare disability 3. Changes in contrast enhancement measurements 4. Changes in Lutein and Zeaxanthin plasma concentrationsTimepoint: Day 0 Day 45 and Day 90

Secondary

MeasureTime frame
1. To assess the safety of the product through Safety assessments like hematology, biochemistry (Lipid profile, LFT, RFT), and Urine analysis & feedback questionnaires. 2. Change in Photostress recovery time. Timepoint: Hematology, biochemistry (Lipid profile, LFT, RFT), and Urine analysis & feedback questionnaires Day 0 Day 90 Change in Photostress recovery time Day 0 & Day 45 & Day 90

Countries

India

Contacts

Public ContactSravani T

Botanic Healthcare Pvt Ltd

research1@botanichealthcare.net7995688815

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026